AMH Testing: What Does It Reveal About Ovarian Reserve and Fertility?

Anti-Müllerian hormone (AMH) is measured through a blood test and is widely used as a marker of ovarian reserve, primarily reflecting the remaining follicular pool. AMH levels generally decline with age as ovarian reserve decreases.

AMH testing is particularly useful during fertility assessment and treatment planning. In assisted reproduction, it can help clinicians anticipate ovarian response to stimulation and estimate the number of oocytes that may be retrieved during an IVF cycle.

However, AMH should not be interpreted as a standalone fertility test. A low AMH level does not mean that natural conception is impossible, while a high level does not guarantee pregnancy.

Importantly, AMH primarily reflects oocyte quantity rather than quality. On its own, it is a poor predictor of spontaneous conception, and female age remains a substantially stronger predictor of reproductive potential.

AMH results should therefore be interpreted within the broader clinical context, including age, medical and reproductive history, menstrual pattern, and, when appropriate, additional hormonal testing and antral follicle count by ultrasound.

The value of AMH lies in providing clinically useful information about ovarian reserve and anticipated response to fertility treatment—not in providing a definitive prediction of an individual’s ability to conceive.